February 22, 2010 Obecure Is Granted Methods and Composition Patents Covering Adjunctive Use of Betahistine

February 16, 2010 Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA

October 25, 2009 IOptima Receives European Patent Approval for its IOPtiMateTM Laser System

October 25, 2009 IOPtima Launches OT-135

October 01, 2009 Dr. Floyd Taub Joins Zetiq Scientific Advisory Board

September 23, 2009 Zetiq Team Publishes Article in Journal of Histotechnology

August 10, 2009 IOPtima Receives CE Approval of its IOPtiMate(TM) Laser System for Treatment of Glaucoma

June 15, 2009 Obecure Achieves Successful Results in its Proof of Concept Study on Histalean and Olanzapine

January 20, 2009 Obecure Completes Patient Enrollment for Phase IIb Trial with HistaleanTM in Obesity

January 08, 2009 Zetiq Reports Success in Clinical Trial Aimed to Identify and Diagnose Cervical Cancer

December 24, 2008 IOPtima Glaucoma Treatment Shows Sustained Success

September 23, 2008 Obecure Recruits First Patient in Phase II Obesity Study in Pre-Menopausal Women

June 15, 2008 IOPtima Successfully Completes Initial Clinical Study For Glaucoma Using Novel Laser-Based Therapy

April 09, 2008 Obecure Signs Strategic Agreement with Farmaceutici-Formenti of the Grunenthal Group for Manufacturi

November 30, 2007 Top Analyst Calls Bio-Light Stock Undervalued

November 07, 2007 IOPtima Completes Pre-Clinical Trials for Novel Laser-Based Therapy for Glaucoma

August 07, 2007 The Whites of their Eyes: IOptima

August 01, 2007 IOPtima Completes Development of Novel Laser-Based Therapy for Glaucoma

July 11, 2007 Zetiq Completes Cancer Diagnosis Kit

June 25, 2007 Obecure Completes Treatment of Patients in Phase II Obesity Trial

May 16, 2007 Obecure Initiates Phase II Study to Examine Effect of OBE101 on Plasma Lipids in Patients Treated Wi

April 11, 2007 Obecure Completes Patient Enrollment for Phase II Obesity Trial

March 13, 2007 Obecure Initiates Phase II Weight Gain Prevention Study for Patients Taking Zyprexa

March 06, 2007 Bio-Light to allocate 5 million shares to Menorah-Mivtachim

February 11, 2007 Obecure to Investigate Effect of Flagship Drug on Cholesterol

January 24, 2007 Obecure Recruits First Patient in Phase II Obesity Study

January 22, 2007 Eli Lilly to support OBEcure Phase II trials

January 21, 2007 Rodman and Renshaw Investments Selected to Lead Obecure Private Placement in US

December 12, 2006 NIH Will Conduct Clinical Trials on Flagship Product OBE101

November 28, 2006 Chief Scientist Approves Grant to Allergica

November 20, 2006 Dr. Joshua Degani Named CEO of IOPtima

September 04, 2006 Obecure receives FDA approval for PHASE II Clinical Trials

July 21, 2006 ObeCure Receives Permission from Canada for Clinical Trial

July 20, 2006 ObeCure To Enter the Appetite Stimulant Market

June 18, 2006 Dr. Yaffa Beck Appointed CEO of ObeCure

June 14, 2006 Allergica signs development accord with Dow Pharmaceuticals

June 06, 2006 Bio-Light Public Offering Raises NIS 30.6 Million

May 18, 2006 Bio-Light Institutional Placement Oversubscribed

May 17, 2006 Allergica Patent Request Approved

May 15, 2006 Allergica signs contract with US institute for development of asthma drug

April 27, 2006 ObeCure Metabolite Twice As Effective

April 06, 2006 Zetiq: Diagnostic Kits To Be Ready Within 3 Months

April 01, 2006 A new Israeli solution for a weighty problem

March 26, 2006 Obecure May Proceed to Phase 2 Clinical Trials

March 16, 2006 Obecure Term Sheet to Raise Up to $1.5M

March 13, 2006 Zetiq Submits 7 New Patent Requests

March 13, 2006 Optotech Patent Approved in U.S.

February 21, 2006 OBEcure Reports New Findings

February 06, 2006 Dr. Yaffa Beck Joins Allergica as Chairman

February 03, 2006 Dr. Nir Barak To Lecture at Texas Conference   Hebrew ver.

January 15, 2006 Allergica To Team With Tel Aviv University.